Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Poxel
Poxel
FDA Review: Alnylam, Cytokinetics, Eli Lilly and More
BioSpace
Sun, 10/9/22 - 06:06 pm
FDA
Alnylam
Cytokinetics
Eli Lilly
Owlet
Boston Cell Standards
Kiromic Biopharma
Entera Bio
Transcenta Holdings
Kira Pharmaceuticals
Kite Pharma
Poxel
Seneca Therapeutics
Poxel pivots to different programs, but questions abound over imeglimin
Fierce Biotech
Mon, 07/12/21 - 10:46 am
Poxel
NASH
diabetes
imeglimin
Poxel posts phase 3 diabetes data ahead of approval decision
Fierce Biotech
Thu, 09/24/20 - 10:14 am
Poxel
diabetes
clinical trials
imeglimin
Japan
As NASH shifts again, the focus remains on Genfit’s big readout
EP Vantage
Wed, 12/18/19 - 10:53 am
NASH
Genfit
elafibranor
Pfizer
Boehringer Ingelheim
Gilead Sciences
Poxel
Takeda
Intercept Pharma
Poxel taking two shots at NASH as pharma waits on FDA’s Ocaliva verdict
Pharmaforum
Wed, 11/20/19 - 10:17 pm
Intercept Pharma
Poxel
NASH
Ocaliva
PXL065
PXL770
Trial sets up 2020 filing for Poxel’s novel diabetes drug
Pharmaforum
Wed, 04/10/19 - 11:40 pm
Poxel
Japan
diabetes
type 2 diabetes
clinical trials
imeglimin
In a strategic switch, Sumitomo Dainippon bags rights to a PhIII diabetes drug from Poxel in $300M deal
Endpoints
Mon, 10/30/17 - 11:05 am
Sumitomo Dainippon
diabetes
clinical trials
imeglimin
Poxel